Progeroid syndrome

Progeroid syndromes are a heterogeneous group of rare genetic disorders characterized by clinical features that resemble premature aging (progeria). These conditions affect multiple body systems and share overlapping features including growth retardation, lipodystrophy (loss of subcutaneous fat), skin atrophy, alopecia or sparse hair, skeletal abnormalities, and characteristic facial features such as a triangular face with a pointed chin and prominent eyes. Depending on the specific subtype, patients may also develop insulin resistance, diabetes mellitus, cardiovascular disease, osteoporosis, and neurodegeneration. The term 'progeroid syndrome' (Orphanet code 139033) serves as a broad classification encompassing multiple distinct entities, including but not limited to Hutchinson-Gilford progeria syndrome, Werner syndrome, Cockayne syndrome, and various other conditions with accelerated aging features. The underlying genetic causes are diverse and involve mutations in genes related to DNA repair, nuclear envelope structure (such as LMNA), telomere maintenance, or other fundamental cellular processes. Because this Orphanet entry represents a grouping of progeroid conditions, the inheritance pattern, age of onset, and specific clinical presentation vary considerably depending on the precise diagnosis. Some forms present at birth or in early childhood with severe growth failure and rapid aging, while others manifest later in life. Treatment is largely supportive and symptom-directed, as no curative therapy exists for most progeroid syndromes. Management may include cardiovascular monitoring, metabolic support, physical therapy, dermatologic care, and orthopedic interventions. For Hutchinson-Gilford progeria specifically, the farnesyltransferase inhibitor lonafarnib has received FDA approval, representing a significant therapeutic advance for that particular subtype.

Common questions about Progeroid syndrome